Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
Open Access
- 28 November 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (12), 1642-1647
- https://doi.org/10.1038/sj.bjc.6603497
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancerBritish Journal of Cancer, 2006
- A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinomaInvestigational New Drugs, 2006
- Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancerBritish Journal of Cancer, 2006
- Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancerGastric Cancer, 2006
- Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal AdenocarcinomaJournal of Clinical Oncology, 2005
- Phase I Evaluation of Continuous 5-Fluorouracil Infusion Followed by Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric CancerJapanese Journal of Clinical Oncology, 2005
- Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancerGastric Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal Of Cancer, 1998
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996